Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation (Q26824355)

main subject

multiple drug resistance

0 references

1 reference

1 reference

C. Q. Xia

1

1 reference

P. G. Smith

series ordinal

2

1 reference

language of work or name

1 reference

December 2012

1 reference

published in

Molecular Pharmacology

1 reference

volume

82

1 reference

issue

6

1 reference

page(s)

1008-21

1 reference

Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients

cites work

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Identification of xanthones as selective killers of cancer cells overexpressing the ABC transporter MRP1.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Association of multi‐drug resistance gene polymorphisms with pancreatic cancer outcome

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

ABCG2 (BCRP) expression in normal and malignant hematopoietic cells

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

CD34+ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of Bcl-2 and MDR1 genes than CD34- cells in childhood AML

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

siRNA-mediated down-regulation of P-glycoprotein in a Xenograft tumor model in NOD-SCID mice

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

The effect of glucosylceramide synthase on P-glycoprotein function in K562/AO2 leukemia drug-resistance cell line

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Calcein accumulation as a fluorometric functional assay of the multidrug transporter

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Regulation of drug transporter expression by oncostatin M in human hepatocytes

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Rapid diagnosis of multidrug resistance in cancer by electrochemical sensor based on carbon nanotubes-drug supramolecular nanocomposites

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Synthesis and in vivo evaluation of ¹⁸F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Rapid determination of multidrug resistance-associated protein in cancer cells by capillary electrophoresis immunoassay.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

BCRP mRNA expression v. clinical outcome in 40 adult AML patients.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Is resistance useless? Multidrug resistance and collateral sensitivity

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Rapid detection of ABC transporter interaction: potential utility in pharmacology.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Structural, mechanistic and clinical aspects of MRP1.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Considerations in the design and development of transport inhibitors as adjuncts to drug therapy

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonylbenzoyl 5'-adenosine: evidence for an ATP analogue that interacts with both drug-substrate-and nucleotide-binding sites

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

P-glycoprotein recognition of substrates and circumvention through rational drug design

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Poloxamines display a multiple inhibitory activity of ATP-binding cassette (ABC) transporters in cancer cell lines

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Development of multidrug-resistance convertors: sense or nonsense?

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

OCT-1 as a determinant of response to antileukemic treatment.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Multidrug Efflux Pumps and Cancer Stem Cells: Insights Into Multidrug Resistance and Therapeutic Development

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

The drug resistance-related protein LRP is the human major vault protein

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Targeting multidrug resistance in cancer

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Synthesis, molecular structure, and validation of metalloprobes for assessment of MDR1 P-glycoprotein-mediated functional transport

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Reversal of MDR1 gene-dependent multidrug resistance in HL60/HT9 cells using short hairpin RNA expression vectors

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Multidrug resistance: can new drugs help chemotherapy score against cancer?

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Ex vivo reversal of chemoresistance by tariquidar (XR9576).

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

No influence of 3435C>T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

The human ATP-binding cassette (ABC) transporter superfamily

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Imaging of multidrug resistance in cancer

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Dodging Drug-Resistant Cancer with Diamonds

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Roles of sildenafil in enhancing drug sensitivity in cancer.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Clinical significance of ABCB1 genotyping in oncology

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Expression of lung resistance protein and multidrug resistance-related protein (MRP1) in pediatric acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

An anti-apoptotic pattern correlates with multidrug resistance in acute myeloid leukemia patients: a comparative study of active caspase-3, cleaved PARPs, Bcl-2, Survivin and MDR1 gene.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Prognostic factors in elderly patients with AML and the implications for treatment

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

hOCT 1 and resistance to imatinib

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Adhesion of human platelets to serum amyloid A

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Amonafide: a potential role in treating acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Probing multidrug resistance P-glycoprotein transporter activity with SPECT radiopharmaceuticals

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Multidrug resistance in the chronic lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Enhanced invasiveness in multidrug resistant leukemic cells is associated with overexpression of P-glycoprotein and cellular inhibitor of apoptosis protein

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

MRP1 polymorphisms (T2684C, C2007T, C2012T, and C2665T) are not associated with multidrug resistance in leukemic patients.

1 reference

https://api.crossref.org/works/10.1124%2FMOL.112.079129

7 January 2021

release_y55pwpbuffakpdvg3fjpykmkz4

Identifiers

DOI

10.1124/MOL.112.079129

0 references

Fatcat ID

0 references

PubMed publication ID

22826468

1 reference